Introduction: The Brazilian National Health System (Sistema Único de Saúde - SUS) aims to ensure universal access to health and comprehensive care for the population. Current bottlenecks affect the quality and reach of health services, impacting the implementation of health guidance documents, such as National Clinical Protocols and Therapeutic Guidelines (CPTG), which compromise assessing and treating of various diseases, such as bipolar disorder (BD). Data provided by the Information Technology Department of SUS (DATASUS) can be a useful tool for mapping the healthcare scenario. Objective: To evaluate the pattern of consumption of recommended medicines for BD in Brazil. Methods: Data regarding outpatient dispensation of atypical antipsychotics (quetiapine, olanzapine, risperidone, clozapine) and lamotrigine between March/2016 and March/2023 were downloaded from DATASUS website. The variables of interest were extracted using the TabWin program. Databases were manipulated to carry out descriptive analyses. Defined daily dose (DDD) indicators were calculated and a trend analysis was carried out using Prais-Winsten regression (p<0,05). Results: From March/2016 to March/2023 there were 3,391,491 drug dispensations for the treatment of BD in Brazil. All medicines showed an increasing trend in the number of dispensations, especially quetiapine 200 mg (Average Incremental Monthly Rate=11,76%; IC95%:3,55-20,63; p=0,005). There was a growing trend in the number of dispensations for patients under 18 years, mainly those aged 15 to 17 years (60,569; 48.17%). Regarding sex, dispensation for women was most frequent (70.4%). There was a growing trend of the DDD per 100,000 inhabitants per day for all the medicines (p<0,05), but clozapine had the fastest increase (Average Incremental Annual Rate = 80,00%; IC95%:37,27-136,04; p<0,003). Conclusion: The growing trend in the consumption of atypical antipsychotics and lamotrigine for BD is warning, which may reflect an increase in access to medicines, but also more BD diagnoses, especially among children and adolescents. The accelerated growth in the consumption of clozapine was unexpected, since it is a drug of last choice according to the CPTG in Brazil.